AZ, Heptares In Possible $500m+ Oncology Deal
This article was originally published in Scrip
Executive Summary
Japan-headquartered Sosei Group's $400m acquisition of Heptares Therapeutics could prove to be a money spinner as the biotech unit has signed an immuno-oncology focused partnership with pharma major AstraZeneca plc, potentially worth $500m.
You may also be interested in...
Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation
An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.
Juno Picks Up A2a Receptor Via Redox Acquisition
Juno Therapeutics Inc. has followed in the footsteps of some of its big pharma rivals, Novartis and AstraZeneca, by acquiring RedoxTherapies, Inc. for its small molecule adenosine A2a (A2a) receptor antagonist vipadenant.
Heptares-Powered Sosei's Incoming CEO Explains What Happens Next
Japanese company Sosei conducted a master stroke last year when it acquired UK biotechnology company Heptares as its in-house R&D engine. Deal after quality deal has ensued, and Sosei's share price has rocketed by more than 400%. Scrip's Sukaina Virji spoke to Sosei's COO – and CEO-elect – Peter Bains to find out what happens next.